newsfilter
← Latest News
Business Wire·

Xencor Reports Third Quarter 2024 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter